Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Depomed (DEPO) Share Price
News headlines about Depomed (NASDAQ:DEPO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Depomed earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.2010847425176 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s analysis:
- Depomed Inc : Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Encourages Investors with Losses to Contact the Firm (4-traders.com)
- DEPO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17 … (businesswire.com)
- Depomed Inc Shares Down 72.9% Since SmarTrend’s Sell Call (DEPO) (mysmartrend.com)
- DEPO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017 (finance.yahoo.com)
- Depomed Inc (DEPO) Needle Moving on Volume – Evergreen Caller (evergreencaller.com)
A number of equities analysts recently issued reports on the company. Mizuho reduced their target price on Depomed from $13.00 to $11.00 and set a “neutral” rating for the company in a research note on Thursday, May 25th. Royal Bank Of Canada reduced their target price on Depomed from $19.00 to $13.00 and set a “sector perform” rating for the company in a research note on Wednesday, May 10th. Piper Jaffray Companies restated a “neutral” rating and issued a $9.00 target price (down previously from $10.00) on shares of Depomed in a research note on Wednesday, August 9th. Janney Montgomery Scott lowered Depomed from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $18.00 to $8.00 in a research note on Tuesday, August 8th. Finally, BidaskClub lowered Depomed from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $14.59.
Shares of Depomed (DEPO) traded down 0.65% during midday trading on Thursday, reaching $6.08. The company’s stock had a trading volume of 929,902 shares. Depomed has a 52 week low of $5.86 and a 52 week high of $27.02. The company has a 50 day moving average of $8.77 and a 200-day moving average of $11.77. The stock’s market capitalization is $382.97 million.
Depomed (NASDAQ:DEPO) last announced its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by $0.52. Depomed had a negative net margin of 26.02% and a negative return on equity of 45.03%. The business had revenue of $100 million during the quarter, compared to analysts’ expectations of $100.40 million. During the same period in the previous year, the company posted $0.27 earnings per share. Depomed’s quarterly revenue was down 14.3% on a year-over-year basis. Equities research analysts predict that Depomed will post $0.48 earnings per share for the current year.
In other Depomed news, insider Arthur J. Higgins bought 15,000 shares of Depomed stock in a transaction dated Monday, June 12th. The stock was acquired at an average cost of $9.92 per share, with a total value of $148,800.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.59% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Depomed (DEPO) Share Price” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-depomed-depo-share-price/1534793.html.
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.